Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size is USD 3.36 Billion in 2026

Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market (By Indication: Infectious Causes, Non-infectious Causes, and UTI; By Mode of Administration: Injectable and Oral; By End-user: Hospital & Ambulatory Surgical Centers and Specialty Clinics; By Product Type: Urinary Tract Infection (UTI), Autoimmune Diseases, Meningitis, Pneumonia, and Others; By Application: Specialty Clinics, Hospital & Ambulatory Surgical Centers, and Others) Industry Size, Share, Growth, Trends 2026 to 2035.

Report Code : 440 | Published : 04 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 3.13 Bn

Forecast Year,

USD 6.27 Bn

CAGR, 2026 - 2035

7.20%

Report Coverage

Asia Pacific

Download Databook

The Asia Pacific systemic inflammatory response syndrome (SIRS) treatment market is projected to grow from USD 3.13 billion in 2025 to USD 6.27 billion by 2035, registering a CAGR of 7.20%, driven by rising critical care demand and improving treatment access.

Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 3.13 Billion
Market Size in 2026	USD 3.36 Billion
Market Size by 2035	USD 6.27 Billion
CAGR 2026 to 2035	7.20%
Base Year	2025
Forecast Period	2026 to 2035

The Asia Pacific Systemic Inflammatory Response Syndrome Treatment market size was estimated at USD 3.13 billion in 2025 and is expanding at a CAGR of 7.20 % from 2026 to 2035. The market growth is driven by expanding healthcare infrastructure and demand for cost-effective treatment.

Segments	Shares (%)
Infectious causes	58%
Non-infectious causes	27%
UTI	15%

Infectious causes - Infectious Causes lead the segment, with a share of 58%, driven by the high prevalence of sepsis, pneumonia, and other infections that commonly trigger systemic inflammatory response syndrome (SIRS).
Non-infectious causes - Non-infectious Causes hold a significant portion, with a share of 27%, supported by conditions such as trauma, burns, and pancreatitis contributing to SIRS cases.

Segments	Shares (%)
Injectable	72%
Oral	28%

Injectable - Injectable dominates the segment, with a share of 72%, driven by the need for rapid drug delivery and immediate clinical response in critical care settings. And supported by improving healthcare infrastructure and growing access to critical facilities.
Oral - Oral holds a smaller portion, with a share of 28%, driven by affordability and accessibility. It is commonly used for maintenance therapy and recovery phases.

Segments	Shares (%)
Hospital & Ambulatory Surgical Centers	78%
Specialty Clinics	22%

Hospital & Ambulatory Surgical Centers - Hospital & Ambulatory Surgical Centers dominate the segment, with a share of 78%, driven by the need for intensive monitoring, emergency care, and advanced treatment infrastructure.
Specialty Clinics - Specialty Clinics hold a smaller portion, with a share of 22%, supported by outpatient care, follow-up treatment services and specialized service care.

Segments	Shares (%)
Urinary Tract Infection (UTI)	20%
Autoimmune Diseases	18%
Meningitis	16%
Pneumonia	30%
Others	16%

Urinary Tract Infection (UTI) - Urinary Tract Infection (UTI) holds a significant portion, with a share of 20%, supported by increasing infection rates and complications leading to systemic inflammation.
Autoimmune Diseases - Autoimmune Diseases account for a notable share, with a share of 18%, driven by chronic inflammatory conditions contributing to SIRS development.

Segments	Shares (%)
Specialty Clinics	17%
Hospital & Ambulatory Surgical Centers	75%
Others	8%

Hospital & Ambulatory Surgical Centers - Hospital & Ambulatory Surgical Centers dominate the segment, with a share of 75%, driven by the high volume of critical care treatments and emergency interventions.
Specialty Clinics - Specialty Clinics hold a moderate share, with a share of 17%, supported by post-acute care and specialized treatment services.

Top Companies in the Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market

GlaxoSmithKline
AstraZeneca
CytoSorbents Corporation
Cardinal Health
Asahi Kasei
ConvaTec
CHIESI Farmaceutici
Smith & Nephew

Segments Covered in the Report

By Indication

Infectious causes
Non-infectious causes
UTI

By Mode of administration

Injectable
Oral

By End-user

Hospital and ambulatory surgical centers
Speciality Clinics

By Product Type

Urinary Tract Infection (UTI)
Autoimmune Diseases
Meningitis
Pneumonia
Others

By Application

Specialty Clinics
Hospital & Ambulatory Surgical Centers
Others

List of Tables & Figures

List of Tables

Table 1: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, 2025–2035 (USD Billion)
Table 2: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, by Indication, 2025–2035 (USD Billion)
Table 3: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, by Mode of Administration, 2025–2035 (USD Billion)
Table 4: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, by End-user, 2025–2035 (USD Billion)
Table 5: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, by Product Type, 2025–2035 (USD Billion)
Table 6: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Size, by Application, 2025–2035 (USD Billion)
Table 7: Asia Pacific SIRS Treatment Market Size – Infectious Causes, 2025–2035 (USD Billion)
Table 8: Asia Pacific SIRS Treatment Market Size – Non-infectious Causes, 2025–2035 (USD Billion)
Table 9: Asia Pacific SIRS Treatment Market Size – UTI, 2025–2035 (USD Billion)
Table 10: Asia Pacific SIRS Treatment Market Size – Injectable, 2025–2035 (USD Billion)
Table 11: Asia Pacific SIRS Treatment Market Size – Oral, 2025–2035 (USD Billion)
Table 12: Asia Pacific SIRS Treatment Market Size – Hospital & Ambulatory Surgical Centers, 2025–2035 (USD Billion)
Table 13: Asia Pacific SIRS Treatment Market Size – Specialty Clinics, 2025–2035 (USD Billion)
Table 14: Asia Pacific SIRS Treatment Market Size – Urinary Tract Infection (UTI), 2025–2035 (USD Billion)
Table 15: Asia Pacific SIRS Treatment Market Size – Autoimmune Diseases, 2025–2035 (USD Billion)
Table 16: Asia Pacific SIRS Treatment Market Size – Meningitis, 2025–2035 (USD Billion)
Table 17: Asia Pacific SIRS Treatment Market Size – Pneumonia, 2025–2035 (USD Billion)
Table 18: Asia Pacific SIRS Treatment Market Size – Others, 2025–2035 (USD Billion)
Table 19: Asia Pacific SIRS Treatment Market Size – Specialty Clinics (Application), 2025–2035 (USD Billion)
Table 20: Asia Pacific SIRS Treatment Market Size – Hospital & Ambulatory Surgical Centers (Application), 2025–2035 (USD Billion)

List of Figures

Figure 1: Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, 2025–2035 (USD Billion)
Figure 2: Asia Pacific Market Share, by Indication, 2025 (%)
Figure 3: Asia Pacific Market Share, by Mode of Administration, 2025 (%)
Figure 4: Asia Pacific Market Share, by End-user, 2025 (%)
Figure 5: Asia Pacific Market Share, by Product Type, 2025 (%)
Figure 6: Asia Pacific Market Share, by Application, 2025 (%)
Figure 7: Asia Pacific Infectious vs Non-infectious Market Share, 2025 (%)
Figure 8: Asia Pacific Injectable vs Oral Market Share, 2025 (%)
Figure 9: Asia Pacific UTI Treatment Market Forecast, 2025–2035 (USD Billion)
Figure 10: Asia Pacific Pneumonia Treatment Market Growth Opportunity Map, 2025–2035 (% CAGR)

Research Methodology

Related Databooks

March 2026